Skip to content

LifeSci IR

Investors
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

LifeSci IR

Investors

Press Releases

Choose Year
Search Press Releases

Found 211 Results

September 2, 2020

Minerva Neurosciences to Present at Citi’s 15th Annual BioPharma Virtual Conference

August 13, 2020

Minerva Neurosciences to Present at JMP Securities CNS Forum

August 3, 2020

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

July 27, 2020

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020

July 1, 2020

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

June 1, 2020

REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

May 29, 2020

Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

May 4, 2020

Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates

April 27, 2020

Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020

March 24, 2020

MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA

«...5 678 9...20...»

IR Contact

FIRST NAME LAST NAME
COMPANY NAME
EMAIL@COMPANY.COM

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Copyright © 2026 LifeSci IR | Powered by Astra WordPress Theme

Scroll to Top